Semaglutide has emerged as a groundbreaking treatment for chronic diseases. This synthetic glucagon-like peptide-1 (GLP-1) receptor agonist acts upon stimulating the pancreas to produce more insulin and reducing glucagon production.
Furthermore, semaglutide possesses potential application